The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma.
The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma.
复制标题
DOI：
10.1186/s12885-022-10002-x
复制
发表时间：
2022-08-23
期刊：
影响因子：
3.8
通讯作者：
中科院分区：
文献类型：
--
作者：
乐伐替尼适用于减少一氧化氮（NO）的产生并促进血管生成。然而，据我们所知，没有数据支持接受乐伐替尼治疗HCC的患者中NO与临床应答之间的相关性。因此，我们研究了不可切除的肝细胞癌（HCC）患者接受乐伐替尼治疗后，NO水平变化率与包括不良事件（AE）在内的临床应答之间的相关性。本研究使用先前从另一项研究中收集的数据进行。我们招募了70名接受乐伐替尼治疗晚期或不可切除HCC的患者。通过硝酸还原酶将硝酸盐（NO3−）转化为亚硝酸盐（NO2−），然后基于Griess试剂定量NO2−来测量NO。为了确定乐伐替尼是否影响不可切除HCC患者的NO，我们评估了乐伐替尼给药后NO相对于基线的变化率对最大治疗应答和SAE的影响。乐伐替尼给药后，观察到NO的变化率为0.27至4.16。乐伐替尼的临床应答与NO变化率之间无差异（p = 0.632）。然而，发生AE的患者NO的变化率显著低于未发生AE的患者（p = 0.030）。当NO率降低< 0.8被定义为NO的临床显著降低（CSRN）时，CSRN组的无进展生存期（PFS）和总生存期（OS）显著低于非CSRN组（分别为p = 0.029和p = 0.005）。NO水平降低与乐伐替尼给药后AE的发生和预后不良相关。血清NO变化率可用作接受乐伐替尼治疗HCC患者的预测标志物。在线版本包含补充材料，可通过10.1186/s12885-022-10002-x获得。
Lenvatinib is appropriate for reducing the production of nitric oxide (NO) and facilitating as block angiogenesis. However, to our knowledge, there are no data that support the correlation between NO and clinical response in patients who received lenvatinib therapy for HCC. Therefore, we investigated the correlation between the change rate of NO levels and clinical responses including adverse events (AEs) after lenvatinib therapy for unresectable hepatocellular carcinoma (HCC). This study was conducted using previously collected data from another study. We enrolled 70 patients who received lenvatinib for advanced or unresectable HCC. NO was measured by converting nitrate (NO3−) to nitrite (NO2−) with nitrate reductase, followed by quantitation of NO2− based on Griess reagent. To determine whether lenvatinib influences NO in unresectable HCC, we evaluated the influence of the change rate of NO from baseline after administration of lenvatinib on maximal therapeutic response and SAE. After lenvatinib administration, a change rate in the NO from 0.27 to 4.16 was observed. There was no difference between the clinical response to lenvatinib and the change rate of NO (p = 0.632). However, the change rate of NO was significantly lower in patients with AEs than in those without AEs (p = 0.030). When a reduction in NO rate of < 0.8 was defined as a clinically significant reduction of NO (CSRN), the CSRN group had significantly worse progression-free survival (PFS) and overall survival (OS) than the non-CSRN group (p = 0.029 and p = 0.005, respectively). Decreased NO levels were associated with the occurrence of AEs and worse prognosis after lenvatinib administration. Change rate in serum NO can be used as predictive markers in patients receiving lenvatinib therapy for HCC. The online version contains supplementary material available at 10.1186/s12885-022-10002-x.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-20-4219
发表时间：
2021-09-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
通讯作者：
--
影响因子：
4.6
作者：
Azuma S;Uojima H;Chuma M;Shao X;Hidaka H;Nakazawa T;Kondo M;Numata K;Iwabuchi S;Kako M;Maeda S;Koizumi W;Atsuda K
通讯作者：
Atsuda K
影响因子：
2.9
作者：
HURSHMAN, AR;MARLETTA, MA
通讯作者：
MARLETTA, MA
影响因子：
13.8
作者：
Iwakiri Y;Kim MY
通讯作者：
Kim MY
影响因子：
4.6
作者：
Ohya, Kazuki;Kawaoka, Tomokazu;Aikata, Hiroshi
通讯作者：
Aikata, Hiroshi